TRANSFAC FACTOR TABLE, Release 2017.2 - public - 2017-06-30, (C) QIAGEN

AC T04494 XX ID T04494 XX DT 16.05.2001 (created); mas. DT 07.11.2013 (updated); din. CO Copyright (C), QIAGEN. XX FA FXR XX SY BAR; bile acid receptor; farnesoid X activated receptor; HRR-1; HRR1; NR1H4; retinoid X receptor interacting protein 14; RIP-14; RIP14. XX OS rat, Rattus norvegicus OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; rodentia; myomorpha; muridae; murinae XX GE G002744 Nr1h4. XX CL C0002; CC (rec); XX SF form heterodimers with RXR-alpha [1] [4] [5]; SF for heterodimer, see rat FXR:RXR-alpha T05318; SF bile acid responsiveness is mediated by the FXR LBD and requires dimerization with RXR-alpha [4]; SF 89% amino acid identity in the DNA-binding domain and only 45 % in the ligand-binding domain to Xenopus FOR1 T05174 and FOR2 T05175 [3]; XX CP (embryo:) expressed in liver, kidney and gut (embryonic day 19.5) [1]; (adult:) kidney (in situ: renal-tubule-tissue like medullary rays and medullary stripe) and liver [1]; expression restricted to above mentioned isoprenoidogenic tissues, which are known to have significant flux through mevalonate pathway [1] [1]. XX FF activator as a heterodimer with RXR-alpha; FF activated by natural ligands: bile acids (e.g. chenodeoxycholic acid) [2] [4] [5]; FF potential ligands: juvenile hormone III and farnesol [1]; FF member of a new signaling system in higher organisms regulated by intracellular metabolites like farnesol [1]; FF inhibits transactivation by LXR-alpha probably by competition for the common heterodimerization partner [4]; XX IN T15971 NFkappaB; rat, Rattus norvegicus. IN T01345 RXR-alpha; human, Homo sapiens. XX MX M07256 V$FXRRXR_Q5. MX M01268 V$FXR_Q2. MX M00631 V$FXR_Q3. MX M03790 V$FXR_Q5. MX M03795 V$LXR_Q6. MX M00964 V$PXR_Q2. XX BS R19190. BS R29615. XX DR TRANSPATH: MO000028341. DR UniProtKB: Q62735; XX RN [1]; RE0016189. RX PUBMED: 7774010. RA Forman B. M., Goode E., Chen J., Oro A. E., Bradley D. J., Perlmann T., Noonan D. J., Burka L. T., McMorris T., Lamph W. W., et a. l. RT Identification of a nuclear receptor that is activated by farnesol metabolites RL Cell 81:687-693 (1995). RN [2]; RE0016194. RX PUBMED: 10334993. RA Parks D. J., Blanchard S. G., Bledsoe R. K., Chandra G., Consler T. G., Kliewer S. A., Stimmel J. B., Willson T. M., Zavacki A. M., Moore D. D., Lehmann J. M. RT Bile acids: natural ligands for an orphan nuclear receptor RL Science 284:1365-1368 (1999). RN [3]; RE0017935. RX PUBMED: 11867625. RA Seo Y. W., Sanyal S., Kim H. J., Won D. H., An J. Y., Amano T., Zavacki A. M., Kwon H. B., Shi Y. B., Kim W. S., Kang H., Moore D. D., Choi H. S. RT FOR, a novel orphan nuclear receptor related to farnesoid X receptor RL J. Biol. Chem. 277:17836-17844 (2002). RN [4]; RE0018127. RX PUBMED: 10360171. RA Wang H., Chen J., Hollister K., Sowers L. C., Forman B. M. RT Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. RL Mol. Cell 3:543-553 (1999). RN [5]; RE0023349. RX PUBMED: 10334992. RA Makishima M., Okamoto A. Y., Repa J. J., Tu H., Learned R. M., Luk A., Hull M. V., Lustig K. D., Mangelsdorf D. J., Shan B. RT Identification of a nuclear receptor for bile acids. RL Science 284:1362-1365 (1999). RN [6]; RE0050748. RX PUBMED: 12718893. RA Mi L. Z., Devarakonda S., Harp J. M., Han Q., Pellicciari R., Willson T. M., Khorasanizadeh S., Rastinejad F. RT Structural basis for bile acid binding and activation of the nuclear receptor FXR. RL Mol. Cell 11:1093-1100 (2003). RN [7]; RE0079199. RX PUBMED: 23124354. RA Catalano S., Panza S., Malivindi R., Giordano C., Barone I., Bossi G., Lanzino M., Sirianni R., Mauro L., Sisci D., Bonofiglio D., Ando S. RT Inhibition of Leydig tumor growth by farnesoid X receptor activation: the in vitro and in vivo basis for a novel therapeutic strategy. RL Int. J. Cancer 132:2237-2247 (2013). XX //